Faculty profile

Amina Zoubeidi

ResearcherUrologic SciencesUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Amina Zoubeidi

Researcher

Urologic Sciences

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
27 publications in the last five years, latest in 2026.
Senior (last) author on 7 recent papers, a sign of leading a research group.
Principal investigator on 4 research grants (4 CIHR), most recently in 2024.
Supervised 2 trainees who won CIHR awards, most recently in 2014.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

123

Publications

777

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Prostate Cancer Treatment Resistance Ascl1 Chromatin Remodeling Complex Lineage Plasticity Nepc Crc Aggressive Disease

Latest papers

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.
The Journal of clinical investigation · 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.
iScience · 2026
ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.
Molecular cancer research : MCR · 2026

All 123 publications

Latest funding

Stimulated Raman Histology for Real-Time Identification and Risk Stratification of Prostate Cancer
CIHR · 2025 · Co-investigator
$887,400
Interplay between ASCL1 and chromatin remodeling complex in prostate cancer lineage plasticity
CIHR · 2024 · Nominated PI
$918,000
Canada Research Chairs - Tier 1
CIHR · 2020 · Nominated PI
$1,400,000

All 8 grants and awards

123 publications.

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

Yang Y, Zhang X, Venkadakrishnan VB, Zou H, Zheng X, Guo S, Chen CZ, Borowsky AD, Corey E, Evans RM, Gao AC, Dall'Era MA, Zoubeidi A, Lara PN, Kung HJ, Chen X, Beltran H, Chen HW

The Journal of clinical investigation2026

DOI: 10.1172/jci200260 PMID: 41842971

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

Subramani E, Pilié PG, Slack-Tidwell R, Viscuse PV, Kuang X, Kandasamy T, Awad D, Han JJ, Huang L, Peterson CB, Zurita AJ, Subudhi SK, Corn PG, Soundararajan R, Shepherd P, Piyarathna B, Putluri V, Putluri N, Sreekumar A, Wang Y, Zoubeidi A, Mahmud I, Martinez SA, Tan L, Lorenzi PL, Basu S, Jindal S, Sharma P, Logothetis CJ, Thompson TC, Frigo DE, Aparicio AM

iScience2026

DOI: 10.1016/j.isci.2026.116184 PMID: 42291217

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Lorenzin F, Fracassi G, Vannuccini F, Ismail M, Ciani Y, Bevilacqua R, Gasperini P, Carbone FG, Cinalli S, Grist E, Devlies W, Giesen A, Van Goubergen J, Claessens F, Joniau S, Davicioni E, Barbareschi M, Rickman DS, Lunardi A, Attard G, Zoubeidi A, Demichelis F

Molecular cancer research : MCR2026

DOI: 10.1158/1541-7786.mcr-25-1310 PMID: 42329113

New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.

Nouruzi S, Kobelev M, Tabrizian N, Gleave M, Zoubeidi A

EMBO molecular medicine2025Senior author

DOI: 10.1038/s44321-025-00282-8 PMID: 40759791

CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST.

Liu L, Rascón IA, Lin D, Ni Y, Dong X, Xue H, Lin YY, Haegert A, Sar F, Peacock JW, Tombe T, Dusek C, Zoubeidi A, Gleave ME, Collins C, Bénard F, Wang Y, Ong CJ

Cell genomics2025

DOI: 10.1016/j.xgen.2025.100916 PMID: 40499539

LKB1 inactivation unleashes prostate cancer lineage plasticity.

Nouruzi S, Zoubeidi A

Cell research2025Senior author

DOI: 10.1038/s41422-024-01030-2 PMID: 39743629

Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.

Teng M, Guo J, Xu X, Ci X, Mo Y, Kohen Y, Ni Z, Chen S, Guo WY, Bakht M, Ku S, Sigouros M, Luo W, Macarios CM, Xia Z, Chen M, Ul Haq S, Yang W, Berlin A, van der Kwast T, Ellis L, Zoubeidi A, Zheng G, Ming J, Wang Y, Cui H, Lok BH, Raught B, Beltran H, Qin J, He HH

Cancer cell2025

DOI: 10.1016/j.ccell.2025.03.027 PMID: 40250444

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors.

Zhang X, Yang Y, Zou H, Yang Y, Zheng X, Corey E, Zoubeidi A, Mitsiades N, Yu AM, Li Y, Chen HW

Acta pharmaceutica Sinica. B2025

DOI: 10.1016/j.apsb.2025.01.007 PMID: 40370549

Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target.

Zhang X, Yang Y, Zou H, Cai D, Corey E, Zoubeidi A, Lo SH, Yu AM, Evans RM, Chen HW

Proceedings of the National Academy of Sciences of the United States of America2025

DOI: 10.1073/pnas.2513468122 PMID: 41231955

Correction: Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.

Sooreshjani MA, Kamra M, Zoubeidi A, Shah K

Journal of biomedical science2025

DOI: 10.1186/s12929-025-01189-9 PMID: 41207894

Stimulated Raman Histology for Real-Time Identification and Risk Stratification of Prostate Cancer

Co-investigatorCIHR2025Project Grant

Principal investigators: Mannas, Miles P

Keywords: Machine Learning; Near Real-Time; Pathology; Prostate Cancer; Risk Stratification; Stimulated Raman Histology; Stimulated Raman Spectroscopy

$887,400

Interplay between ASCL1 and chromatin remodeling complex in prostate cancer lineage plasticity

Nominated PICIHR2024Project Grant

Principal investigators: Zoubeidi, Amina

Keywords: Ascl1; Chromatin Remodeling Complex; Lineage Plasticity; Nepc; Prostate Cancer; Treatment Resistance

$918,000

Canada Research Chairs - Tier 1

Nominated PICIHR2020Canada Research Chairs - CIHR Funded - Tier 1

Principal investigators: Zoubeidi, Amina

Keywords: Crc

$1,400,000

The role of the lineage oncogene ASCL1 in treatment-induced neuroendocrine prostate cancer

Nominated PICIHR2019Project Grant

Principal investigators: Zoubeidi, Amina

Keywords: Aggressive Disease; Neuroendocrine; Proneural Factor; Prostate Cancer; Transdifferentiation; Treatment Resistance

$841,500

Hormone therapy induces reprogramming to drive aggressive prostate cancer

Nominated PICIHR2018Project Grant

Principal investigators: Zoubeidi, Amina

Keywords: Prostate Cancer

$669,376

A Cancer Stem Cell-Directed Therapy for Enzalutamide-Resistant Prostate Cancer

SupervisorCIHR2014CIHR Fellowship

Principal investigators: Davies, Alastair H

Keywords: Cancer Stem Cells; Enzalutamide-Resistance; Epigenetics; Ezh2; Mechanisms Of Resistance; Phenotypic Plasticity; Prostate Cancer; Reprogramming; Targeted Therapy

$135,000

Rationale for targeting Wnt5a pathway in Enzalutamide Resistant Prostate Cancer.

SupervisorCIHR2014Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Thaper, Daksh

Keywords: Bioinformatics; Cancer Stem Cells; Castration Resistant Prostate Cancer; Drug Resistance; Prostate Cancer

$105,000

The Terry Fox New Frontiers Program on Prostate Cancer Progression (M. Gleave)

Co-investigatorCIHR2010Team Grant: Terry Fox New Frontiers Program in Cancer

Principal investigators: Gleave, Martin E; Chi, Kim N; Collins, Colin C; Cox, Michael E; Guns, Emma S; Ong, Christopher J; Rennie, Paul S; Wang, Yuzhuo

Keywords: Genomic Markers; Prostate Cancer; Targeted Therapies; Translational Research

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Amina Zoubeidi

Research

Latest papers

Latest funding

Targeting Wnt/&#x3b2;-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.

CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST.

LKB1 inactivation unleashes prostate cancer lineage plasticity.

Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors.

Circadian regulator REV-ERB&#x3b1; is a master regulator of tumor lineage plasticity and an effective therapeutic target.

Correction: Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.

Frequent collaborators

Martin Gleave

Yuzhuo Wang

Lucia Nappi

Colin Collins

Richard Sowery

Alejandro Berlin

Katie Houlahan

Artem Cherkasov

Yu Wang

Mathieu Lupien

Ming-Sound Tsao

Marianne Koritzinsky

Michael Cox

Mads Daugaard

Ralph Buttyan

Kim Chi

Jean-Philippe Lambert

Paul Toren

Haissi Cui

Bharati Bapat

Étienne Audet-Walsh

David Uehling

Matthieu Ruiz

Graham Dellaire

Xuesen Dong

Michael Pollak

Benjamin Haibe-Kains

Anne-Marie Mes-Masson

Paul Rennie

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target.